Trial Profile
Phase II trial of FavId (tumor-specific idiotype-KLH) and soluble GM-CSF [granulocyte-macrophage colony-stimulating factors] immunotherapy in patients with stable or progressive grade 1 or 2 follicular B-cell lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Mitumprotimut T (Primary)
- Indications Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 10 Nov 2005 New trial record.